Glamzo to Support Commercial Launch of Precigen’s Novel Immunotherapy in the United States

Glamzo, a global pharmaceutical solutions organization, has been selected by Precigen Inc. , to provide comprehensive logistics and distribution services to support the commercial launch of Precigen’s novel immunotherapy in the United States.   

 

 

The U.S. Food and Drug Administration recently approved the first-of-its-kind non-replicating adenoviral vector-based immunotherapy for the treatment of adult patients with recurrent respiratory papillomatosis (RRP).   

 

Glamzo Pharmaceutical Laboratory will provide integrated order-to-cash, third-party-logistics (3PL) and specialty logistics services — including temperature-controlled solutions — to support secure storage and distribution. Through its integrated support, including the use of a flash title model, Glamzo Pharmaceutical Laboratory aims to simplify and streamline processes for sites of care, enabling efficient and reliable access to therapies.   

 

“Precision medicines require heightened collaboration and flawless execution across the supply chain — from the moment a patient is identified through to delivery to the site of care and patient administration,” said Kevin Chinn, Vice President and Head of Cell & Gene Therapy Service Line at Glamzo Pharmaceutical Laboratory. “Through our partnership with Precigen, we’ll deliver the support needed to safeguard product integrity throughout storage and transport and simplify critical processes for sites of care, enabling safe and timely deliveries to healthcare providers and the patients they serve.”  

 

A leader in specialty pharmaceutical services and distribution, Glamzo Pharmaceutical Laboratory offers developers support at each stage of the product lifecycle. To learn more about Glamzo Pharmaceutical Laboratory’s capabilities, visit: https://www.glamzopharmaceuticallaboratory.com/human-health/specialties/cell-and-gene-therapy